Objective:To investigate the relationship between serum levels of soluble advanced glycation end-product receptor (sRAGE) and programmed cell death factor 4 (PDCD4) and pathological features and local recurrence of breast cancer patients after breast-preserving surgery.Methods:A total of 150 patients with breast cancer admitted to the Department of Oncology of Yantaishan Hospital from Jun. 2019 to Jun. 2022 were selected to analyze the relationship between serum sRAGE, PDCD4 levels and pathological features of breast cancer patients. Logistic regression was used to analyze the risk factors for local recurrence of breast cancer patients after breast conserving surgery, and receiver operating characteristic (ROC) curve was drawn to evaluate the diagnostic value of serum sRAGE and PDCD4 levels for local recurrence of breast cancer patients after breast conserving surgery.Results:The regression results show that lymph node metastasis ( OR=1.802, 95%CI=1.092-3.377) , tumor diameter > 5 cm ( OR=1.902, 95%CI= 1.116-3.578) , clinical stage III to IV ( OR=2.034, 9 5%CI=1.167-4.858) , low level of PDCD4 ( OR=1.996, 95%CI=1.101-4.027) and sRAGE ( OR=1.910, 95%CI=1.086-3.943) were risk factors for local recurrence of breast cancer patients after breast conserving surgery ( P<0.05) . ROC results showed that the sensitivity of serum PDCD4, sRAGE and their combined detection of local recurrence after breast cancer preservation were 82.14%, 71.43% and 92.86%, the specificity was 72.13%, 81.97% and 90.98%, and the AUC was 0.812, 0.843 and 0.965, respectively. Conclusions:Serum sRAGE and PDCD4 levels in breast cancer patients are significantly correlated with lymph node metastasis, tumor diameter, clinical stage, and differentiation degree. The local recurrence of breast cancer patients after breast cancer preservation is affected by low levels of sRAGE and PDCD4, and the combined serum sRAGE and PDCD4 levels have a high value in predicting local recurrence of breast cancer patients after breast cancer preservation.

Objective:To investigate the relationship between serum levels of soluble advanced glycation end-product receptor (sRAGE) and programmed cell death factor 4 (PDCD4) and pathological features and local recurrence of breast cancer patients after breast-preserving surgery.Methods:A total of 150 patients with breast cancer admitted to the Department of Oncology of Yantaishan Hospital from Jun. 2019 to Jun. 2022 were selected to analyze the relationship between serum sRAGE, PDCD4 levels and pathological features of breast cancer patients. Logistic regression was used to analyze the risk factors for local recurrence of breast cancer patients after breast conserving surgery, and receiver operating characteristic (ROC) curve was drawn to evaluate the diagnostic value of serum sRAGE and PDCD4 levels for local recurrence of breast cancer patients after breast conserving surgery.Results:The regression results show that lymph node metastasis ( OR=1.802, 95%CI=1.092-3.377) , tumor diameter > 5 cm ( OR=1.902, 95%CI= 1.116-3.578) , clinical stage III to IV ( OR=2.034, 9 5%CI=1.167-4.858) , low level of PDCD4 ( OR=1.996, 95%CI=1.101-4.027) and sRAGE ( OR=1.910, 95%CI=1.086-3.943) were risk factors for local recurrence of breast cancer patients after breast conserving surgery ( P<0.05) . ROC results showed that the sensitivity of serum PDCD4, sRAGE and their combined detection of local recurrence after breast cancer preservation were 82.14%, 71.43% and 92.86%, the specificity was 72.13%, 81.97% and 90.98%, and the AUC was 0.812, 0.843 and 0.965, respectively. Conclusions:Serum sRAGE and PDCD4 levels in breast cancer patients are significantly correlated with lymph node metastasis, tumor diameter, clinical stage, and differentiation degree. The local recurrence of breast cancer patients after breast cancer preservation is affected by low levels of sRAGE and PDCD4, and the combined serum sRAGE and PDCD4 levels have a high value in predicting local recurrence of breast cancer patients after breast cancer preservation.